|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-4-26
|
|
pubmed:abstractText |
Angiotensin II blockade and spironolactone effectively reduces proteinuria in humans. To clarify the mechanisms of the beneficial effect of blockade of both aldosterone and angiotensin II, we associated the aldosterone antagonist eplerenone to an angiotensin-converting enzyme inhibitor (ACEI) and examined the effect on renal transforming growth factor (TGF)-beta expression and oxidative stress by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in the Dahl salt-sensitive rat with heart failure (DSHF).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aldosterone,
http://linkedlifedata.com/resource/pubmed/chemical/Aldosterone Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/NADPH Oxidase,
http://linkedlifedata.com/resource/pubmed/chemical/Reactive Oxygen Species,
http://linkedlifedata.com/resource/pubmed/chemical/Sodium-Potassium-Exchanging ATPase,
http://linkedlifedata.com/resource/pubmed/chemical/Spironolactone,
http://linkedlifedata.com/resource/pubmed/chemical/Superoxide Dismutase,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/eplerenone,
http://linkedlifedata.com/resource/pubmed/chemical/trandolapril
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0931-0509
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1314-22
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17324946-Aldosterone,
pubmed-meshheading:17324946-Aldosterone Antagonists,
pubmed-meshheading:17324946-Angiotensin II,
pubmed-meshheading:17324946-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:17324946-Animals,
pubmed-meshheading:17324946-Cardiac Output, Low,
pubmed-meshheading:17324946-Drug Synergism,
pubmed-meshheading:17324946-Hypertension,
pubmed-meshheading:17324946-Indoles,
pubmed-meshheading:17324946-Kidney,
pubmed-meshheading:17324946-Male,
pubmed-meshheading:17324946-NADPH Oxidase,
pubmed-meshheading:17324946-Oxidative Stress,
pubmed-meshheading:17324946-Rats,
pubmed-meshheading:17324946-Rats, Inbred Dahl,
pubmed-meshheading:17324946-Reactive Oxygen Species,
pubmed-meshheading:17324946-Sodium-Potassium-Exchanging ATPase,
pubmed-meshheading:17324946-Spironolactone,
pubmed-meshheading:17324946-Superoxide Dismutase,
pubmed-meshheading:17324946-Transforming Growth Factor beta
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
|
|
pubmed:affiliation |
Division of Nephrology and Endocrinology, Department of Internal Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
